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Abstract: Melatonin is known to influence a variety of biological processes including circadian rhythms, neuroendocrine, and
cardiovascular and immune functions as well as thermoregulation. Melatonin is the chief secretory product of the pineal gland,
although it is also produced in other organs. In this study, in vitro effects of melatonin on 6-phosphogluconate dehydrogenase from
human erythrocytes and in vivo effects of melatonin on 6-phosphogluconate dehydrogenase from rat (Sprague-Dawley) erythrocytes
were studied. Human erythrocyte 6-phosphogluconate dehydrogenase was purified in 3 steps, namely haemolysate preparation,
ammonium sulphate fractionation (35-65%) and 2´,5´-ADP Sepharose-4B affinity gel chromatography. 6-Phosphogluconate
dehydrogenase was purified with a recovery rate of 88.8%, 2254-fold. Enzyme activity was spectrophotometrically measured using
Beutler’s method. In addition, 6-phosphogluconate dehydrogenase activity was inhibited in vitro by melatonin. For the in vivo study,
16 adult male Sprague-Dawley rats weighing 200-250 g were used. The animals were divided into 2 equal groups of 8 animals each:
the control and melatonin-treated groups. Both groups were kept under special conditions for 6 h. Melatonin at a 10 mg/kg
pharmacological dosage also inhibited the enzyme significantly (P < 0.05) for 3 h invivo. However, enzyme activity increased to the
normal level at 6 h.
Key Words: Erythrocytes, Melatonin, 6-Phosphogluconate dehydrogenase, In vivo, In vitro

Introduction
6-Phosphogluconate dehydrogenase (6-Phospho-Dgluconate: NADP+ oxidoreductase, E.C.1.1.1.44; 6PGD)
is an important enzyme of the pentose phosphate
metabolic pathway. The enzyme catalyses the oxidative
decarboxylation of 6-phosphogluconate to ribulose 5phosphate and CO2 with a concomitant reduction of
NADP+ to NADPH. 6PGD was characterised from the
standpoint of the kinetic and acid base chemical
mechanisms (1-5). This reaction yields NADPH, which
protects the cell against oxidative agents by producing
reduced glutathione (6). NADPH is also a coenzyme
participating in the synthesis of a number of biomolecules
such as fatty acids, steroids, and some amino acids (7,8).
In the case of NADPH deficiency, the concentration of
reduced glutathione in living systems declines, resulting in
cell death. For this reason, 6PGD can be defined as an
antioxidant enzyme (9,10). Many drugs are known to

affect several body enzymes in vivo (11-13). If any drug
inhibits 6PGD, the decreased NADPH and GSH will cause
cell damage, especially in older erythrocytes, resulting in
severe health problems (13). It has been reported that
Vitamin C stimulates 6PGD (14). However, no studies
could be found on the in vitro and in vivo effects of
various drugs on erythrocyte 6PGD.
Melatonin is a pineal-derived product. It is synthesised
enzymatically from serotonin by the sequential action of
serotonin N-acetyltransferase and hydroxyindole-Omethyltransferase. It is also produced in other organs and
found in all body fluids after its release from the pineal
gland (15). Melatonin is known to participate in many
important physiological functions, including the control of
seasonal reproduction, and also influences the immune
system and circadian rhythms (16-19). It plays a key role
in a number of disorders, such as seasonal depression
(19). In addition, melatonin stimulates several antioxidant
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enzymes such as superoxide dismutase and gluthatione
peroxidase (20). Moreover, melatonin directly scavenges
and also stimulates the activity of endogenous antioxidant
enzymes such as glutathione peroxidase (21). However,
there is no information about the effect of melatonin on
6PGD. In the present study, we investigated the effects of
melatonin on red blood cell 6PGD activity.

In vitro effect of melatonin on 6PGD
In order to determine the effects of melatonin on
6PGD, various concentrations of melatonin (0.86, 1.72,
2.58, 4.30, and 6.88 mM) were added to separate tubes
containing purified enzyme. The enzyme activity was
measured in these tubes taking the tubes containing no
melatonin as the control. This value was taken as 100%
activity.

Materials and Methods
Materials
6-Phosphogluconate (6PGA), nicotinamide adenine
dinucleotide phosphate (NADP+), melatonin, tris
(hydroxymethyl)aminomethane (Tris) and the other
chemicals were purchased from Sigma.

Preparation of the haemolysate and haemoglobin
estimation
Fresh blood samples from the rats were placed into
EDTA containing tubes and centrifuged (15 min, 2500 x
g). Plasma and buffy coat (leucocytes) were removed.
The package of red cells was washed 3 times with KCl
(0.16 M) and haemolysate was prepared in 5 volumes of
ice-cold water and then centrifuged (+4 °C, 10000 x g)
for 30 min to remove the ghosts and intact cells. The
haemoglobin (Hb) concentration in haemolysate was
determined by the cyanmethaemoglobin method (22).

Activity determination
Enzymatic activity was measured using Beutler’s
method (23). In this spectrophotometric measurement,
the reaction medium maintained at 25 °C contained 0.1
mM Tris-HCl (pH 8.0) with 0.5 mM EDTA, 10 mM
MgCl2, 0.2 mM NADP+, and 0.6 mM 6PGD in a total
volume of 1 ml. NADPH produced in the reaction mixture
was measured at 340 nm. One unit of enzyme (EU)
activity was defined as the enzyme amount reducing 1
µmol of NADP+ per 1 min at 25 °C, pH 8.0.

Protein determination
Protein content in ammonium sulphate supernatant
was quantified spectrophotometrically at 595 nm using
Bradford’s method (24). Bovine serum albumin was used
as standard protein.
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In vivo effect of melatonin on 6PGD
Sixteen adult male Sprague-Dawley rats weighing
200-250 g were used for the experiment. The animals
were divided into 2 equal groups of 8 animals each: the
control and melatonin-treated groups. Both groups were
kept under special conditions (in a windowless room, at a
temperature of 22 °C, with a light on for 14 h) for 6 h.
Before intramuscular melatonin injection, the control
blood samples (0.5 ml of whole blood with EDTA) were
obtained from the animals; a pharmacological dosage of
melatonin (10 mg/kg) was injected into the group. Blood
samples were taken from each group 1, 3, and 6 h after
injection. Haemolysates were prepared from all blood
samples as described above. Haemoglobin levels and
6PGD activity were then determined.

Statistical analysis
Results are presented as mean ±SD. All parameters
were analysed using one-way variance analysis. The least
significant difference multiple range test was used to
compare the mean values. Acceptable significance was
recorded when P values were <0.05. Statistical analysis
was performed using SPSS (version 9.0, Chicago, IL,
USA).

Results and Discussion
As can be seen in Table 1, in the first step, the
haemolysate sample was precipitated using ammonium
sulphate (35-65%). Impurities were thus significantly
eliminated. Then 2´,5´-ADP Sepharose 4B column
chromatography was performed. The enzyme 6PGD of
the rat erythrocytes was purified 2254-fold by this
method.
It is well known that many chemicals have adverse
effects on the organism when used for therapeutic or
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Table 1. Purification scheme of 6-phosphogluconate dehydrogenase from human erythrocytes.

Activity
(EU/ml)

Total
volume
(ml)

Protein
(mg/ml)

Total
protein
(mg)

Total
activity
(EU)

Specific
activity
(EU/mg)

Yield
(%)

Purification
fold

Haemolysate

0.021

25

10.22

255.5

0.4

0.0015

100

1

Ammonium sulphate
precipitation (35-65%)

0.50

12

0.275

3.30

0.312

0.094

48

62.7

2´,5´-ADP Sepharose
4B chromatography

0.071

5

0.021

0.105

0.355

3.38

88.8

2254

Steps

other purposes (25). These effects may be dramatic and
systematic (26). A good example of this is how in 1926
pamaquine used for malaria treatment caused severe
adverse effects in patients within a few days, resulting in
black urination, hyperbilirubinaemia, a dramatic decrease
in blood Hb levels, and finally death in cases of severe
G6PD deficiency (27). Similarly, acetazolamide inhibits
carbonic anhydrase (CA), giving rise to severe diuresis
(28).

activity in vitro. Five different melatonin concentrations
were used to determine the effects on human 6PGD
activity. As can be seen in Figure, it was evident from the
in vitro studies that the 6PGD was inhibited up to 6.88 x
10-5 M by melatonin. For the in vivo studies, 20 units
from adult (200-250 g) Sprague-Dawley rats were
selected. The 6PGD activity of the control group was 188
± 19.3 EU /gHb. The melatonin injection was performed
on the control group intramuscularly. After the melatonin
injection, the enzyme activities of the groups were
measured at 1, 3 and 6 h. The corresponding activities
were 120 ± 13.8, 106 ± 12.5 and 193 ± 16.1,
respectively, and the greatest inhibition was found 3 h
after injection (Table 2).

Melatonin reduced the activity of cytochrome c
oxidase, the enzyme respiratory chain (29). In addition,
this hormone reduced the lipase esterase and alkaline
phosphatase activity of the liver in male mink (30).
However, there is no information about the effect of
melatonin on human erythrocyte 6PGD.

As be can be seen in Table 2, the in vivo studies
showed that melatonin inhibited enzyme activity by
36.2% at 1 h (P < 0.05) and by 43.6% at 3 h (P <

Figure shows the in vitro effects of the melatonin on
the enzyme activity. All concentrations inhibited enzyme
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Figure. Activity (%) vs. melatonin concentration plot of 6PGD.
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Table 2. In vivo effects of melatonin (10 mg/kg body weight) on rat
red blood cell 6-phosphogluconate dehydrogenase activity (n
= 8).
Time after administration (h)
0
1
3
6

6PGD activity (EU/gHb)
188
120
106
193

±
±
±
±

In conclusion, we demonstrated that melatonin
reduced activity under in vitro and in vivo conditions on
human and rat erythrocyte 6-phosphogluconate
dehydrogenase, respectively.

19.3
13.8
12.5
16.1
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0.05). Six hours after melatonin treatment, a slight
activation appeared, but this value was not statistically
significant (P > 0.05).
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